4th Novel Conjugate Summit

The 4th Novel Conjugate Summit explores innovations in bioconjugation, targeted drug delivery, and novel therapeutic strategies for enhanced efficacy and precision in treatment.

Topics

• Targeted protein degraders as next-generation antibody payloads
• Advancing nucleotide-based therapeutics with antibody-oligonucleotide conjugates
• Overcoming tumor heterogeneity via multispecific targeting
• Discovery of precision antibody-drug conjugates with novel degrader payloads
• Bright Peak immunoconjugates as a new class of multifunctional biologics
• Optimizing bispecific ADCs for increased tumor specificity
• Bicycle conjugates for precision targeting of solid tumors
• Delivery of a BET protein degrader via a CEACAM6-targeted ADC
• Pioneering targeting ligands for groundbreaking conjugates
• Endosomal escape vehicle-conjugated morpholino oligomer therapeutics
• Design considerations for optimizing pharmacokinetic profiles
• Challenges in process development of antibody-radio conjugates
• Hormone-peptide conjugates as next-generation targeted therapy
• Leveraging peptide-drug conjugates for unlocking new oncology targets
• Pushing the envelope with bi-specific ADCs using novel glycobiotechnology
• Technology for degrader-antibody conjugates with mAb-like pharmacokinetics
• Highlighting cutting-edge discovery platforms for novel bioconjugates
• Revolutionizing bioconjugate synthesis and process development
• Targeted 225Ac therapy using small molecule, peptide, and antibody vectors
• Leveraging bispecific antibody-drug conjugates for high tumor selectivity

Who should Attend

• Oncology researchers
• Pharmaceutical scientists
• Bioconjugation specialists
• Medicinal chemists
• Biotech startup executives
• Regulatory affairs professionals
• Antibody-drug conjugate developers
• Translational medicine experts
• Clinical development professionals
• Immunotherapy researchers
• CMC and process development scientists
• Protein engineering specialists
• Academic researchers in targeted therapies
• Pharmacokinetics and drug metabolism scientists
• Radiopharmaceutical developers
• Biopharma investors and strategists
• Drug formulation and delivery experts
• Biomedical engineers
• Preclinical toxicologists
• Technology transfer and IP specialists